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Abstract
Background & Aims—Patients with Barrett’s esophagus (BE) show increased risk for
developing esophageal adenocarcinoma and are routinely examined using upper endoscopy with
biopsy to search for neoplastic changes. Angle-resolved low coherence interferometry (a/LCI)
uses in vivo depth-resolved nuclear morphology measurements to detect dysplasia. We assessed
the clinical utility of a/LCI in the endoscopic surveillance of BE patients.
Methods—Consecutive patients undergoing routine surveillance upper endoscopy for Barrett’s
esophagus were recruited at two endoscopy centers. A novel, endoscope compatible a/LCI system
was used to measure the mean diameter and refractive index of cell nuclei in esophageal
epithelium at 172 biopsy sites in 46 patients. At each site, an a/LCI measurement was taken and
correlated with a concurrent endoscopic biopsy. Each biopsy was assessed histologically and
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classified as normal, non-dysplastic BE (NDBE), indeterminate for dysplasia, low-grade dysplasia
(LGD), or high-grade dysplasia (HGD). The a/LCI data from multiple depths were analyzed to
evaluate its ability to differentiate dysplastic from non-dysplastic tissue.
Results—Pathology characterized five of the scanned sites as HGD, eight as LGD, seventy-five
as NDBE, seventy as normal tissue types and fourteen as indeterminate for dysplasia. The a/LCI
nuclear size measurements separated dysplastic from non-dysplastic tissue at a statistically
significant (P < .001) level for the tissue segment 200-300μm beneath the surface with an
accuracy of 86% (147/172). A receiver operator characteristic (ROC) analysis indicated an area
under the curve (AUC) of 0.91, and an optimized decision point gave 100% (13/13) sensitivity and
84% (134/159) specificity.
Conclusions—These preliminary data suggest a/LCI is accurate in detecting dysplasia in vivo in
BE patients.
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Introduction
Esophageal adenocarcinoma is rapidly increasing in incidence in the United States.1
Barrett’s esophagus (BE), a metaplastic transformation of the esophageal lining from
squamous epithelium to a specialized columnar epithelium containing goblet cells, has long
been recognized as a precursor lesion to esophageal adenocarcinoma.2, 3 BE is thought to
progress through stages of dysplasia before developing into esophageal adenocarcinoma.
The incidence of adenocarcinoma in patients with BE increases with the degree of dysplasia
from approximately 0.5% per year4, 5 in non-dysplastic BE, rising to as high as 15-20% per
year in subjects with HGD.6, 7 Current techniques for endoscopic monitoring of the disease
represent a large cost burden, the value of which has been called into question.8
The current procedure commonly used for monitoring tissue health in Barrett’s esophagus
patients consists of periodic endoscopic surveillance with systematic biopsies. Four-
quadrant biopsies are taken at 1-2 centimeter intervals along the entire segment of affected
esophageal tissue. Surveillance procedures call for periodic examinations, with the
frequency dictated by the degree of dysplasia observed.4 This approach has inherent
limitations. Due to the need for sample processing, there is a time delay between endoscopy
and diagnosis, requiring separate procedures for detection of dysplasia and treatment. In
addition, diagnostic uncertainty often results due to the difficulties in analyzing the small,
often histologically ambiguous tissue samples obtained during a standard biopsy, limiting
inter-observer agreement between pathologists.9, 10 There is also a risk of misdiagnosis due
to sampling error in the affected tissue because of the small surface area that can be
examined using four-quadrant biopsy techniques, estimated to be between four and six
percent of the metaplastic epithelium.11
Developments in interventional therapies, such as radiofrequency ablation,6 photodynamic
therapy,12 and cryotherapy,13 show great promise for management of Barrett’s esophagus,
with the potential to reduce the risk of cancer in patients found to have dysplasia. The
limitations of currently accepted methods for monitoring and evaluating the disease state of
Barrett’s esophagus patients, coupled with the benefit from early diagnosis of dysplasia,
points to an unmet need for additional tools to improve detection of dysplasia.
One promising approach for improving dysplasia detection is the use of optical biopsy
techniques based on light scattering measurements. The dominant interaction between light
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and tissue is elastic scattering, where light is delivered in one direction and scattered in
another without a change in energy (wavelength). By controlling the delivery and collection
geometry, it is possible to collect backscattered light and analyze its characteristics in order
to infer morphological structure within tissues, such as the size and distribution of cell
nuclei. Several optical biopsy technologies have been developed for use during endoscopic
procedures, including light scattering spectroscopy,14, 15 four-dimensional elastic light-
scattering fingerprinting (4D-ELF),16 endoscopic confocal microscopy17 and fluorescence
imaging.18-21
We report the application of a novel light scattering technique, angle-resolved low
coherence interferometry (a/LCI), that analyzes the angular distribution of elastically
scattered light to make depth-resolved measurements of both the size and index of refraction
of cell nuclei, as a means to evaluate dysplasia in the setting of BE. This technology was
adapted for probe-based delivery through the instrument channel,22 and its operating
characteristics assessed in a clinical study.
Methods
Clinical Study Protocol
Fifty consecutively enrolled subjects undergoing routine endoscopic surveillance for BE at
one of two tertiary centers specializing in the care of subjects with BE provided informed
consent for this study. All subjects were receiving acid suppressive therapy with proton
pump inhibitors once to twice daily, and none had undergone previous ablative therapy or
displayed evidence of esophagitis. Patients with a history of esophageal cancer or
esophageal resection were excluded. The characteristics of the patient population for this
study are shown in Table 1.
In each patient, 3-6 mucosal locations of columnar mucosa in the tubular esophagus were
imaged using the a/LCI system (Figure 1) at random points. A matching histological biopsy
was obtained at each imaged point. The protocol for image and biopsy acquisition was as
follows: upon selection of an imaging site, the endoscopist deployed the a/LCI fiber probe
through the accessory channel and into the esophagus. The probe was brought into contact
with the surface of the tissue and 10-30 data acquisitions of 25 milliseconds each were taken
at each imaging location. Real-time analysis of image quality was performed in the room by
a technician, who advised re-positioning of the probe in the case of poor signal quality.
Following data collection with the a/LCI system, the fiber probe was removed from the
instrument channel, and biopsy forceps were deployed to collect a tissue biopsy at precisely
the same location. Guidance for localization of the physical biopsies was facilitated by a
clearly visible, but temporary, indentation left by an approximately 1 mm protruding rim on
the surface of the a/LCI probe (white arrow in Figure 1B). The entire study consisted of 172
unique paired biopsies, for which a total of 3,397 data scans were acquired and analyzed.
The biopsies collected from the scanned sites were fixed, sectioned, stained with
hematoxylin and eosin and each analyzed by a pathologist at a central pathology laboratory
with expertise in GI pathology to assess the presence and degree of dysplasia. Pathologists
were blinded to the results of the a/LCI scan. The biopsies were classified as normal
(squamous, gastric, squamo-columnar junction), non-dysplastic BE, BE indeterminate for
dysplasia, BE positive for LGD, and BE positive for HGD. If biopsies at the squamo-
columnar junction contained both squamous and gastric tissue, they were grouped with the
‘normal’ tissue types as they do not contain goblet cells. Any biopsy found to have dysplasia
was confirmed by a second expert pathologist, with discrepancies resolved by consensus.
The histological assessments of dysplasia were compared to measurements taken by the a/
LCI system in order to determine the ability of a/LCI to identify dysplasia. The study design
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was approved by the Institutional Review Boards at the University of North Carolina at
Chapel Hill and the Thompson Cancer Survival Center in Knoxville, TN.
Angle Resolved Low Coherence Interferometry (a/LCI)
The a/LCI method is based on measuring the angular distribution of scattered light as a
function of depth beneath the tissue surface. The scattered light from each tissue layer is
analyzed to determine the mean size and average density of the cell nuclei in the probed
area.23, 24 The morphology of the cell nuclei is determined by comparison of the angular
scattering data to the predictions of Mie theory, an analytical model of electromagnetic
scattering by homogenous spheres.25, 26 While this theory assumes a spherical nucleus,
mathematical27, 28 and experimental29, 30 studies have shown that accurate structural
measurements of spheroids can be made with this approach. Further, previous studies of
neoplastic transformation in animal models have shown that this approximation provides
high sensitivity and specificity for discriminating non-dysplastic from dysplastic tissues.
31-33 For the current study, the experimental data were analyzed by comparison to a
database of Mie theory scattering solutions that describe the elastic light scattering patterns
for a range of cell nuclei sizes and indices of refraction relative to the surrounding cytoplasm
(representing nucleus density).
Depth resolution is achieved in a/LCI by using interferometry in a manner similar to that
used in Fourier-domain optical coherence tomography.34 Light that has been scattered from
the tissue is mixed with a reference light beam that has traveled a matched optical path,
generating an interference pattern which appears as a spectral modulation in the detected
signal. The spectrally resolved data are Fourier transformed to separate the scattered light by
its pathlength within the tissue. The depth resolution that is achieved by this technique is set
by the bandwidth of the light delivered.
Endoscopic Fiber Probe
We developed a fiber-optic probe for clinical a/LCI operation that is compatible with the
accessory channel of a standard endoscope.22, 35 The probe is 230 cm in length, long
enough to pass through the accessory channel of a 105 cm working distance gastroscope,
and 2.5mm in diameter, compatible with the instrument channel of most endoscopes. The
fiber probe is encased in a plastic sheath, for protection of the internal components, which
also provides low friction to facilitate movement through the accessory channel. The distal
end of the probe transmits light to the esophageal lumen via a polarization-maintaining
optical fiber. To enable a/LCI measurements, the probe face is placed in contact with the
tissue to provide a consistent geometrical interface. The incident light is formed into a
collimated beam, approximately 0.4 mm in diameter and delivered to the tissue at an oblique
angle using a small lens incorporated in the probe tip, as shown in Figure 1C. This lens also
serves to collect the backscattered light as a function of scattering angle. The 0.4mm size of
the beam represents the field of view probed by the a/LCI system in each data acquisition.
The scattered light is relayed back to the a/LCI base unit via a 2.3m long imaging fiber
bundle (Schott NA, Southbridge, MA, USA), which is 1.1mm in diameter and contains
18,000 optical fibers arranged in a parallel orientation relative to the delivery fiber.
Clinical a/LCI System
The a/LCI optical engine consists of a light source used to generate light for delivery to the
tissue and an interferometer used to analyze the light returned from the tissue by the fiber
probe (Figure 1A).22 The light source used by the a/LCI system is a superluminescent light-
emitting diode (SLD – Superlum Ltd., Moscow, Russia) with a center wavelength of 832nm
and 19 nm bandwidth. The large bandwidth is required to achieve depth resolution. The
SLD output light is coupled into an optical fiber and split into reference and sample arms.
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The polarization of the light passed into the sample arm is controlled by an in-line polarizer
before it is introduced into a polarization-maintaining fiber in the probe. The imaging fiber
bundle in the probe returns the angular scattering pattern of light from the tissue to the
optical engine. The light emerging from the proximal face of the fiber bundle is imaged onto
the input slit of a spectrometer (SP 2150i, PI Acton, Acton, MA), after it is mixed with the
pathlength-matched light from the reference fiber. The system is controlled by a laptop
computer, which provides synchronized control of the delivery light and analyzes the
detected signal in real time. The a/LCI systems allow for sub-second data collection (25
milliseconds per image) and processing of the scattered light, which enables multiple a/LCI
data points to be acquired without significantly increasing procedure time. Because of the
short acquisition time, respiratory variation does not impact image quality.
Image Data Analysis
The data collected during the optical biopsies were processed using the following
procedures: Each scan was normalized to account for the specific characteristics of the fiber
probe used during acquisition and then analyzed using the procedure described in Brown et
al.,23 in which the angular scattering pattern contributed by the cell nuclei for each depth is
isolated and compared to a predetermined database of scattering patterns, generated using
Mie theory. The best fit for the detected signal from this database is selected using chi-
squared analysis, and is used to identify the nuclear size and index of refraction for each
tissue site and sub-surface location. Each analyzed point must pass three data quality
checkpoints to confirm that a unique morphological determination has been found, including
signal strength, comparison to the next best size and comparison to a null solution.23 Scans
with inadequate signal for evaluation were discarded.
Each scan is analyzed in 50 μm depth increments and processed across the uppermost 500
μm of the tissue, yielding up to ten nuclear size and index of refraction measurements for
each depth scan. For each scan, the surface of the tissue was identified from the depth
resolved data and the uppermost 300 μm of the tissue was segmented into three 100 μm
segments for analysis, by combining up to two measurements from each of the 50μm depth
increments. This depth range covers the expected thickness of the epithelium of the probed
tissue. To ensure that sufficient tissue scattering was present to generate a meaningful result,
scans of low amplitude (caused by normal esophageal motion) were rejected. To generate a
consensus size and index of refraction measurement for each segment from an individual
paired biopsy site, the results for all individual qualifying scans taken at the site were
averaged in order to create a unique size measurement for that specific site. Data from each
of the three 100μm tissue layers were analyzed and compared independently to pathological
diagnosis to determine if correlation with dysplastic state was possible at a statistically
significant level.
Statistical Analysis
Statistical analyses were used to assess the association of dysplasia with morphological
nuclear characteristics after adjusting for other relevant factors. Specifically, repeated
measures logistic regression models were fit. For each model, the outcome variable was
dichotomized as dysplasia vs. no dysplasia. The main predictor was the morphological
nuclear characteristic (nuclear density or nuclear diameter at a depth of 0-100μm,
100-200μm and 200-300μm, for a total of six models). Potential confounders to be adjusted
for were age, sex, site, baseline diagnosis and clinical diagnosis. A compound symmetric
correlation matrix was used to account for the repeated measures within subjects and
diagnostics were performed to assess the fit of the model to the data. Each of the potential
confounders was entered into a model with the nuclear characteristic and those that proved
statistically significant were included in the final model. P-values associated with type I
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error rates of less than 0.05 were considered statistically significant in this study. Analyses
were done using SAS Version 9.2 (SAS Institute, Cary NC).
The relationship between sensitivity and specificity was determined through the
development of a receiver operating characteristic (ROC) for the collected data. For this
analysis, presence of dysplasia was considered as a binary classifier and nuclear diameter
was used as an evaluation characteristic. In order to evaluate the value of nuclear size as a
predictive classifier, the area under the ROC curve (AUC) was calculated as a fraction of the
maximum possible AUC.
Inter-observer agreement between the a/LCI system and the independent pathologist was
measured using the kappa statistic.36 The kappa statistic provides a framework for
evaluating the agreement between two independent observers of the same data. Agreement
between observers can be assessed by determining a characteristic kappa value between 1




Forty-six patients (46) were scanned with an a/LCI system. Four additional patients were
enrolled but not scanned due to technical difficulties. Typical a/LCI data are shown in
Figure 2. Panel A shows an angle-resolved depth scan, which is created by Fourier-
transforming the interferometric data collected by the spectrometer. Lighter shades of gray
indicate higher intensity, which corresponds to higher levels of scattered light. Depth is
indicated along the horizontal axis, with 0μm corresponding to the interface between the tip
of the fiber probe and the tissue surface. A total of 3,397 scans were obtained, but scans that
yielded low intensity were excluded, resulting in the dataset being reduced in size to 1,866
scans, corresponding to a 45% rejection rate. No patients or biopsies were discarded due to
the rejection of individual scans. The collected data are summed across all angles and
presented as an amplitude-scan (A-scan) in Panel B. This represents scattered light as a
function of depth with tissue layers indicated. For processing, angle-resolved data are
analyzed by depth in 50μm segments, as indicated in Panel B. For each depth segment, an
angular profile of light scattered from the tissue is recovered. Once this angular profile has
been filtered to remove noise, it is fit to the best Mie solution in order to determine its
nuclear size and index of refraction. The creation of a single consensus size and index of
refraction measurement for each depth at each biopsy site allowed the data to be reduced
from 1,866 data points to 516 morphological measurements Panel C shows three example
angular profiles from tissue types with varied pathological diagnoses. These angular profiles
(solid line) are shown along with the best fit theory (dashed line) and the corresponding
nuclear size.
Figure 3 shows a scatter plot of the mean nuclear size and average nuclear density for the
basal epithelial layer (200-300 μm depth segment) for each paired biopsy in the study. From
these data, a simple decision line can be drawn that well separates the samples diagnosed as
normal tissue types versus those diagnosed as dysplastic. Placing the decision line at
11.84μm, as indicated in Figure 3 by the dashed black line, separates the two populations
with maximum sensitivity and high specificity. Using this line, all 13 of the 13 biopsies
pathologically assessed as dysplastic (LGD and HGD combined) were also flagged by the a/
LCI technique as dysplastic (100% sensitivity, 95 % CI is (0.75, 1.00)). For non-dysplastic
tissue (normal, non-dysplastic BE & BE indeterminate for dysplasia), 134 of these 159
biopsy sites were correctly categorized by the a/LCI technique as non-dysplastic (84%
specificity, 95% CI is (0.78, 0.90)). Using the 11.84μm cut-off, the a/LCI technique
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accurately classified dysplastic tissue and non-dysplastic tissue at 147 of 172 biopsy sites
(86% accuracy, 95% CI is (0.80, 0.91)). Use of this optimal decision line yielded a positive
predictive value (PPV) of 34% (13/38) with a 95% CI of (0.20, 0.51) and a negative
predictive value (NPV) of 100% (134/134) with a 95% CI of (0.97, 1.00). When biopsies
demonstrating only squamous or gastric mucosa were disregarded and only biopsies in
which BE is present were considered, then biopsies positive for dysplasia were distinguished
from indeterminate and non-dysplastic BE with a sensitivity of 100% (13/13) with a 95% CI
of (0.75, 1.00) and a specificity of 85% (76/89) with a 95% CI of (0.76, 0.92) using the same
decision line.
Receiver operating characteristic (ROC) curves were generated using nuclear size as the
differentiating variable in order to determine the relationship between sensitivity and
specificity (Figure 4). Biopsies identified in the pathology report as positive for dysplasia
were characterized as diseased tissue (n = 13, true positives), while those identified as either
indeterminate for dysplasia, non-dysplastic Barrett’s esophagus, squamous epithelium,
gastric epithelium or squamo-columnar junction were classified as non-dysplastic tissue (n =
159, true negatives). Biopsies identified as indeterminate for dysplasia (n = 14) were treated
as non-dysplastic in this analysis. The nuclear size data from the 200-300μm layer showed
the strongest distinction between dysplastic and non-dysplastic tissue, with an AUC from the
ROC curve of 0.91 (95% CI: 0.81, 1.00). For the ROC for the data from the first and second
100μm segments of tissue, the AUC values were 0.58 (95% CI: 0.42, 0.75) and 0.52 (95%
CI: 0.36, 0.69) respectively, indicating that differentiation between dysplastic points and
non-dysplastic points at these shallower depths was indiscriminant. ROC analysis indicated
that the optimal decision line to maximize both sensitivity and specificity fell at 11.99μm.
For this study the decision line was placed at 11.84μm, which maximized detection of
dysplasia while sacrificing only a minimum of specificity.
In unadjusted models, nuclear diameters between 0-100μm and 100-200μm and nuclear
density between 200-300μm were not associated with a dysplastic diagnosis. An increase in
nuclear diameter between 200-300μm (p=0.0001), in nuclear density between 0-100μm
(p=0.004) and in nuclear density between 100-200μm (p=0.01) were associated with an
increased likelihood of having dysplasia. Figure 5 shows the average nuclear diameter for all
three 100 μm depth sections for each of the pathological categories (normal tissue, non-
dysplastic BE and dysplasia). Increasing age predicted dysplasia in all models. Additionally,
site of enrollment predicted dysplasia in 5 of the 6 models, with a higher proportion of
subjects recruited at Thompson Cancer Survival Center displaying dysplasia. As a result age
and site of enrollment were included adjusted models as appropriate. In the adjusted models,
nuclear diameter between 0-100μm and 100-200μm, and nuclear density from 100-200μm
were not predictive of dysplasia. Nuclear diameter from the mucosal layer 200-300μm
beneath the surface (p=0.0001) and nuclear density for the 0-100μm deep layer (p = 0.009)
were positively associated with having dysplasia and nuclear density for the 200-300μm
deep layer (p=0.0009) was negatively associated with dysplasia. Regression diagnostics
demonstrated a good fit of all constructed models. These results are summarized in Table 2.
Using the kappa statistic to evaluate inter-observer agreement,36 a/LCI and histological
biopsies agree at the “substantial” level for the distinction of dysplasia from non-dysplastic
Barrett’s (κ = 0.60) and for the distinction of dysplastic versus normal tissue (κ = 0.60).
When the normal tissue and non-dysplastic Barrett’s esophagus are grouped together as
“non-dysplastic”, the inter-observer agreement is “moderate” (κ = 0.45).
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The data presented here demonstrate that a/LCI can detect a statistically significant
enlargement of nuclear size in the basal layer of esophageal tissues found to be positive for
dysplasia by histopathologic evaluation of biopsies. Analysis of the nuclear morphology
data for the 200-300μm depth segment, which contains the basal layer of the epithelium,
shows a correlation between increased nuclear size and the presence of dysplasia. This result
is in agreement with previous a/LCI studies, in which nuclear size and index of refraction
from the basal layer, contained in the third 100μm layer, has been shown to be of particular
diagnostic use.23, 31 The high sensitivity and specificity demonstrated in this study suggests
that a/LCI may have utility in a clinical setting as a guide to target biopsies. Current biopsy
techniques are inherently restricted to evaluating the limited amount of tissue which can be
physically extracted. It has been shown that in up to 25% of cases where dysplasia has been
previously identified, it is not found in follow-up surveillance procedures.6, 37 This is likely
due to the focal nature of the dysplastic changes, combined with sampling error associated
with physical biopsies. Due to the limited tissue coverage, traditional biopsy procedures
would benefit from the use of an adjunct imaging modality with the ability to provide
complementary information that can identify suspicious tissue regions. Upon demonstrating
adequate accuracy in detecting dysplastic tissue, this type of adjunct imaging modality could
be used to improve and perhaps one day supplant histological biopsies in a surveillance
examination. Since optical biopsy allows sampling of more tissue sites in less time and
without the expense and diagnostic limitations associated with histological examination, it
has significant potential to improve surveillance of BE tissues as an adjunct imaging
modality. Further, the specific advantages of the a/LCI system, including rapid data
acquisition and the potential for real-time analysis, could be exploited not only to increase
surveillance coverage of at-risk tissues, but might also open up the possibility of therapeutic
intervention within the same endoscopic session as the diagnostic procedure.
The sensitivity and specificity presented here are consistent with previous studies using this
approach in which a/LCI has been shown to detect esophageal dysplasia in animal and
human tissues. Dysplasia has been identified in situ in a rat carcinogenesis model with 100%
sensitivity and 80% specificity (n=42).31 A follow-on prospective study in this model
showed 91% sensitivity and 97% specificity (n=82) for predicting dysplasia.33 An
endoscopic a/LCI system was able to detect dysplasia with 100% sensitivity and 100%
specificity (n = 18) in ex-vivo human esophagus following resection of dysplastic BE tissue
by esophagogastrectomy.38 A second human study examining dysplasia in BE in situ was
conducted in the pathology laboratory with a portable system, yielding 100% sensitivity and
78% specificity (n = 15).23
Preliminary data are available for several other imaging modalities in detecting dysplasia in
BE. Light-scattering spectroscopy, has also been used to detect dysplasia in patients with BE
(n = 13).10 This technique analyzes the spectral content of scattered light as a function of
wavelength in order to measure the distribution of enlarged nuclei between the tissue surface
and an estimated penetration depth of 100-200μm. The approach was able to detect
dysplasia (low- and high-grade combined) with sensitivity and specificity of 90% each.
Georgakoudi et al. used a tri-modal spectroscopy technique that combines multiple
spectroscopic measurements (fluorescence, reflectance and light-scattering spectroscopy) for
the detection of dysplasia in patients with BE (n = 16).15 In this study, each of the
aforementioned techniques was used to identify the presence of dysplasia. Intrinsic
fluorescence spectroscopy and diffuse reflectance spectroscopy were both able to separate
dysplastic from non-dysplastic tissue with 79% sensitivity and 88% specificity. Light
scattering spectroscopy separated the same sample population with 93% sensitivity and 96%
specificity. When the results of all three techniques are combined, the resulting multi-modal
Terry et al. Page 8













analysis was able to separate diseased tissue (low- and high-grade dysplasia combined) from
non-dysplastic Barrett’s esophagus with 93% sensitivity and 100% specificity.15 A study
conducted by Dunbar et al. used a recently developed confocal endomicroscope to examine
patients with BE (n = 39) to detect neoplasia.39 Confocal endomicroscopy is capable of
generating high-resolution images of the mucosal surface using an intravenously
administered, exogenous contrast agent such as fluorescein. The images obtained in this
study correlate with histology but require physician interpretation of the images to detect
disease. By identifying the presence of irregular cells, the technique was able to predict BE-
associated neoplasia with a sensitivity of 93% and a specificity of 98%. This technique,
however, is typically limited to an image depth of less than 200μm, which does not allow
examination of the tissue depth that was found in this study to possess the most valuable
diagnostic information.
In this study, the nuclear size data gathered from 0-100μm and 100-200μm did not
demonstrate diagnostic value. This may be due to confounding issues such as inflammation
which is expected to preferentially affect the surface of the esophagus, or may be due to the
fact that basal nuclei are most informative in regards to the state of dysplasia. The
differentiation observed for the nuclear size in the 200-300μm depth segment of the
epithelial tissue layer is significant. The ability of a/LCI to analyze this deep layer of tissue
independently of the influence of the surface layers of the epithelium presents a unique
capability not found in other endoscopic optical biopsy techniques used for the evaluation of
Barrett’s esophagus.
The data from this study point to the potential clinical utility for a/LCI. The ability to
provide quantitative depth-resolved measurements of nuclear morphology without the need
for image interpretation or administration of a contrast agent is not found in current
techniques. Alternative approaches, such as enhanced magnification endoscopy and
endoscopic confocal microscopy, are able to provide detailed, high-resolution images of the
epithelium, but these require histological interpretation by the endoscopist.39, 40 These
techniques are also limited to investigation of the surface and topmost 100μm of tissue
respectively, ignoring potentially relevant information regarding deeper tissue layers.
Comprehensive imaging techniques, such as optical coherence tomography (OCT) can
provide information about the entire epithelium, but also require histological interpretation
of the images. In OCT, discrimination of dysplastic tissue is further complicated by the fact
that most OCT systems do not possess the spatial resolution required for measurements of
nuclear morphology.41
A shortcoming of the present study was the dichotomous nature of our outcome variable.
While classifying outcomes as either “dysplastic” or “non-dysplastic” ignores the radically
different clinical implications regarding degrees of dysplasia, it was useful to demonstrate
proof of principle that the device could accurately discern between the two. It was also
pragmatically necessary, given the small numbers of dysplastic biopsies in the study. Further
work will characterize the ability of the device to discriminate between grades of dysplasia.
Another factor which might impact the findings of this study, and therefore limit the utility
of a/LCI, is the high rate of variability between pathologists in the diagnosis of dysplasia in
BE, as cited above.9, 10 Since the “gold standard” for this study was histological reading by
expert pathologists, any errors in classification the pathologists might turn a true positive
into a false positive, or a true negative into a false negative, with respect to a/LCI imaging.
Given the lack of other feasible gold standards for this study, as well as other studies which
seek to validate new methods for detecting dysplasia, future work assessing the long term
outcomes of subjects found to be positive for dysplasia by a/LCI nuclear morphology
measurements but negative for dysplasia by histology, might illustrate the degree to which
human error is impacting the present results.
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In summary, this report presents the first clinical evaluation of a/LCI for detecting dysplasia
in Barrett’s esophagus patients. This in vivo study demonstrates very strong agreement
between pathological identification of dysplasia and nuclear enlargement, as measured using
a/LCI, in the basal layer of epithelium. These results suggest that a/LCI has promise as a
complementary diagnostic tool for physicians in the surveillance of BE patients for
dysplasia. Development of real-time processing software would allow the endoscopist to
identify suspicious tissue sites and collect biopsies in a more targeted and perhaps more
effective manner. The very high NPV would allow an endoscopist to forgo biopsies at sites
with a normal nuclear diameter, while targeting biopsies to more suspicious regions. Any
adjunct imaging tool that can demonstrate an improvement in the ability to identify
dysplasia at an early stage increases the opportunity to implement an effective therapy.
Further studies are planned to validate the findings presented here, and to better define the
ability of a/LCI as a tool for the endoscopic detection of dysplasia, both in the esophagus
and at other organ sites.
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4D-ELF 4-dimensional elastic light-scattering fingerprinting
a/LCI angle-resolved low coherence interferometry
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NDBE Non-dysplastic Barrett’s esophagus
NPV negative predictive value
OCT optical coherence tomography
PPV positive predictive value
ROC receiver operating characteristic
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A) High-level a/LCI system diagram. Inset shows scale of probe tip compared to a U.S.
dime. B) Image showing characteristic mark left by a/LCI probe following deployment,
indicated by the white arrow. C) Detail of the a/LCI probe tip. Light is delivered as a
collimated beam to the tissue. Scattered light is collected across the face of the fiber bundle
for transport back to the a/LCI system.
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Typical a/LCI data. A) Angle-resolved depth scan of light scattered from tissue. Lighter
shades of gray indicate increased amount of scattered light. B) A-scan indicating depth
increments used for processing. Tissue layers are labeled and gray bar indicates basal layer.
C) Example angular scans for three tissue types pictured (solid line) with best fit Mie theory
solutions (dashed line) and size indicated.
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Scatter plot with each biopsy plotted as a function of its nuclear size and density, as
measured by the a/LCI system, and categorized by its pathological diagnosis. Dashed black
line indicates an optimized decision line between the two populations, resulting in 100%
sensitivity and 84% specificity.
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The receiver operator characteristic (ROC) curve for the depth segment between 200-300μm
indicating relationship between sensitivity and specificity for varied decision lines using
nuclear diameter as a discriminator. The gray area indicates the area under the curve (AUC
= 0.91). ROC curves for depth segments from 0-100μm and 100-200μm (not shown) have
an AUC of 0.58 and 0.52 respectively.
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Nuclear size for each of the tissue layers segregated by pathological diagnosis.
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Table 1
Patient characteristics for population of patients scanned in this study.
Demographic Charactersistics of the Study Cohort
Age 38-86 (μ=62, σ=11.6)
Sex 29 Male, 17 Female
Previously detected dysplasia 10/46 (22%)
Previously detected adenocarcinoma 0/46 (0%)
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Table 2
Summary of statistical analysis used to differentiate dysplasia from non-dysplastic tissue in biopsy populations
using both adjusted and unadjusted models. NS indicates that the specified characteristic did not differentiate
dysplasia at a significant level (P < 0.05).
Nuclear Characteristic Variables Adjusted For Unadjusted p-value Adjusted p-value
Nuclear Diameter 0-100μm Age, Site NS NS
Nuclear Diameter 100-200μm Age, Site NS NS
Nuclear Diameter 200-300μm Age, Site 0.0001 0.0001
Nuclear Density 0-100μm Age 0.004 0.009
Nuclear Density 100-200μm Age, Site 0.01 NS
Nuclear Density 200-300μm Age, Site NS 0.0009
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